ERC 5-year Impact Factor
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 17 (1) F1 -17     DOI: 10.1677/ERC-09-0172
Copyright © 2010 by the Society for Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ERC-09-0172v1
17/1/F1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Coppola, V.
Right arrow Articles by Bonci, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coppola, V.
Right arrow Articles by Bonci, D.

FOCUS REVIEW

MicroRNAs and prostate cancer

Valeria Coppola1, Ruggero De Maria1,2 and Désirée Bonci1

1 Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanità, viale Regina Elena 299, 00161 Rome, Italy
2 Department of Experimental Oncology, Mediterranean Institute of Oncology, via Penninazzo 7, 95029 Viagrande, Catania, Italy

(Correspondence should be addressed to V Coppola; Email: valeria.coppola{at}iss.it)

This paper is one of 6 papers that form part of a special Focus Section on microRNAs. The Guest Editors for this section were Professor Alfredo Fusco, Naples, Italy, and Professor Carlo M Croce, Columbus, OH, USA.

Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tools are needed to predict disease severity, choose among the available treatments and establish more effective therapies for advanced prostate cancer. In the last few years, compelling evidence has documented the role of microRNAs as new broad-spectrum oncogenes or tumour suppressor genes, thus their use as diagnostic, prognostic and therapeutic biomolecules is envisaged. This review extensively and critically summarizes the current knowledge about microRNA deregulation in prostate cancer disease, underlining present limits and future perspectives.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
A. Fusco
MicroRNAs: a great challenge for the diagnosis and therapy of endocrine cancers
Endocr. Relat. Cancer, January 29, 2010; 17(1): E3 - E4.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2010 by the Society for Endocrinology.